LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global RNAi technology market since 2019 and the market is poised to grow by USD 1.96 billion during 2020-2024, progressing at a CAGR of ...

Jan. 10, 2011, 8:46 AM EST / Source: GlobeNewswire VANCOUVER, British Columbia, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of ...

PALO ALTO, Calif., April 14 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced study results that demonstrated the ...

In 2011, several big pharma companies dealt serious blows to RNA interference (RNAi) technology by abandoning or reducing their programs. But while RNAi may be down, it is far from out. The discovery ...

AUSTIN, Texas and TOKYO, Sept. 4, 2025 /PRNewswire/ -- According to DataM Intelligence, the RNAi technology market size reached US$ 2.75 Billion in 2024 from US$ 2.51 Billion in 2023 and is expected ...

SAN DIEGO - RNA, a silent guest at the 50th birthday party for its counterpart, DNA, could be having its own coming-out party soon - if expectations become fulfillment, if the current intellectual ...

(MENAFN- EIN Presswire) EINPresswire/ -- The RNA interference (RNAi) technology market has been experiencing remarkable growth recently, driven by advances in genetic research and increasing interest ...

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform.

Farmers looking to gain the upper hand over corn rootworm (CRW) pests have new tools to deploy in the field, thanks to Ribonucleic acid interference (RNAi) technology. RNAi works in CRW as it feeds on ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, ...